Clinical Trial Update: Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 imaging study assessing the performance of 89Zr-TLX250 PET in metastatic triple-negative breast cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• 89Zr-TLX250 (89Zr-TLX250)

Snippet

Sponsor: Institut Cancerologie de l'Ouest | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-12-30